Abstract
BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P
Original language | English |
---|---|
Pages (from-to) | 1341-1344 |
Number of pages | 4 |
Journal | Transplantation |
Volume | 83 |
Issue number | 10 |
DOIs | |
Publication status | Published - May 2007 |
Keywords
- Hepatitis B virus
- Hepatitis delta virus
- Lamivudine
- Liver transplantation
- Outcome
ASJC Scopus subject areas
- Transplantation
- Immunology